Bococizumab is a remarkable anti-PCSK9 antibody efficiently developed to address hypercholesterolemia. Such therapeutic agent interacts with the PCSK9 protein, a key regulator of cholesterol concentrations. By https://www.targetmol.com/compound/bococizumab